Tocilizumab treatment in COVID-19 patients: therapy's side effects and effect on mortality

CONCLUSIONS: Despite the risks of side effects, tocilizumab was used in COVID-19 treatment since it is an interleukin-6 blocker. Although the first publications stated that the treatment could decrease the mortality rate, later meta-analyses did not support these results. Our study also found that using tocilizumab did not make a difference in long-term mortality. We also observed that the known side effects were seen in short-term use.PMID:38497892 | DOI:10.26355/eurrev_202403_35623

Source: Pharmacological Reviews - March 18, 2024 Category: Drugs & Pharmacology Authors: P Ayvat S Kayhan Omeroglu Source Type: research